Factors Influencing Warfarin Dose Requirements in African–Americans
- 22 November 2007
- journal article
- clinical trial
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 8 (11) , 1535-1544
Abstract
African-Americans are under-represented in studies assessing contributors to warfarin response. Our primary objective was to determine whether the genes for cytochrome P450 (CYP) 2C9, nicotinamide adenine dinucleotide phosphate, reduced, quinone oxidoreductase (NQO1) and vitamin K epoxide reductase complex subunit 1 (VKORC1) are associated with warfarin dose requirements in African-Americans. The following factors were assessed: demographics; clinical data; the CYP2C9 Arg144Cys (*2), Ile358Leu (*3) and Asp360Glu (*5); NQO1 Pro187Ser (*1/*2); and VKORC1 G6853C genotypes were analyzed in 115 African-Americans on stable warfarin doses. Allele frequencies were 0.05 for the CYP2C9 *2, *3 or *5 alleles; 0.20 for NQO1 *2; and 0.25 for VKORC1 6853C. Possession of a CYP2C9*2, *3 or *5 allele was associated with a 38% lower warfarin dose compared with the *1/*1 genotype (30 +/- 13 vs 48 +/- 18 mg/week; p = 0.003). Neither the NQO1 *1/*2 nor VKORC1 G6853C genotype was associated with warfarin dose requirements in the population as a whole or in CYP2C9*1 allele homozygotes. Multiple regression analysis revealed that CYP2C9 genotype (p = 0.015), age (p < 0.001) and body surface area (p < 0.001) were jointly associated with warfarin dose requirements, and together explained 33% of the variability in warfarin dose requirements among African-Americans. Our data suggest that CYP2C9 genotype, age and body size are important determinants of warfarin dose requirements in African-Americans. Our data further suggest that the VKORC1 G6853C polymorphism alone may not be useful for predicting warfarin dose requirements in this racial group.Keywords
Funding Information
- New Investigator Award to Cavallari from the American Association of Colleges of Pharmacy and the American Foundation for Pharmaceutical Education
This publication has 47 references indexed in Scilit:
- Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 2007
- Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patientsThrombosis Research, 2007
- Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2Proceedings of the National Academy of Sciences, 2006
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance doseThe Pharmacogenomics Journal, 2005
- VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationThrombosis and Haemostasis, 2005
- Pyrosequencing Method for Genotyping Cytochrome P450 CYP2C8 and CYP2C9 EnzymesClinical Chemistry, 2004
- Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThrombosis and Haemostasis, 2004
- Population pharmacokinetics of racemic warfarin in adult patientsJournal of Pharmacokinetics and Biopharmaceutics, 1985